Transparency is the Victim
By The Hindu,
The Hindu
| 01. 27. 2013
Expansion and proliferation of assisted reproductive technologies (ART) has been facilitated by economic globalisation wherein reproductive tissues like sperm, ova, and uteri are traded like any other commodity to make profit, says a new study, adding that India has emerged as the surrogacy outsourcing capital of the world.
Titled ‘Reproductive Tourism in India: Actors, Agencies and Contemporary Transnational Networks’, the study was conducted by the Centre of Social Medicine and Community Health, JNU, Sama-Resource Group for Women and Health and King’s College London.
The study focuses on the scenario in New Delhi where a large number of private hospitals and government institutions offer ART. It was found that public sector institutions offer only altruistic surrogacy services which are medically indicated. Leading obstetricians and gynaecologists from a top government-run hospital admitted that they have performed in-vitro fertilisation (IVF) in some cases where they were not sure if it was altruistic surrogacy.
One doctor said that she once had a patient, a doctor by profession who bore a surrogate baby for her sister-in-law who was also a doctor, married to a doctor...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...